Late-Onset Maculopapular Eruptions Associated with Elevated Varicella-Zoster Virus Complement-Fixing Antibody Titers following BNT162b2 mRNA COVID-19 Vaccination in Older Adult Japanese Patients: A Cross-Sectional Study

IF 3.7 4区 医学 Q1 DERMATOLOGY Dermatologic Therapy Pub Date : 2024-06-14 DOI:10.1155/2024/2777924
Masahiro Oka, Yosuke Fujii, Sae Murakami
{"title":"Late-Onset Maculopapular Eruptions Associated with Elevated Varicella-Zoster Virus Complement-Fixing Antibody Titers following BNT162b2 mRNA COVID-19 Vaccination in Older Adult Japanese Patients: A Cross-Sectional Study","authors":"Masahiro Oka,&nbsp;Yosuke Fujii,&nbsp;Sae Murakami","doi":"10.1155/2024/2777924","DOIUrl":null,"url":null,"abstract":"<div>\n <p>Diverse cutaneous adverse reactions associated with the messenger RNA-based BNT162b2 coronavirus disease 2019 (COVID-19) vaccine have been reported, usually developing within 3 weeks after the first vaccination. However, the long-term cutaneous effects of this vaccine remain poorly understood. We hypothesized that the BNT162b2 vaccine might trigger late-onset (&gt;4 weeks after the first dose) maculopapular eruptions associated with elevated varicella-zoster virus (VZV) complement-fixing antibody (VZV-CF Ab) titers indicative of recent subclinical VZV reactivation. Therefore, we conducted a hospital-based cross-sectional study at the Dermatology Department of Kita-Harima Medical Center, Ono City, Japan, between July 1, 2021, and June 30, 2022, to investigate the correlations among the BNT162b2 vaccine, maculopapular eruptions, and VZV-CF Ab titers. Fifteen eligible patients (EPs) who experienced maculopapular eruptions on the trunk and extremities no earlier than 4 weeks after the first BNT162b2 vaccine dose and 12 control patients (CPs) were enrolled. The mean age of EPs and CPs was 73.7 and 77.6 years, respectively, and the median interval between the first BNT162b2 vaccination and onset of maculopapular eruptions was 90 days. The median VZV-CF Ab titer of EPs was significantly higher than that of CPs (×8 vs. ×4). Although people of all ages, except children aged ≤12 years, received BNT162b2 vaccinations, all EPs were aged ≥57 years. All EPs presented between July 2021 and March 2022. There were no EPs from April 2022 to December 2023. These results suggest that the BNT162b2 vaccine triggers elevated VZV-CF Ab titer-associated maculopapular eruptions as late-onset cutaneous adverse reactions in older adults. Furthermore, the observation that two EPs concurrently experienced delayed large local reactions, also known as COVID arm, along with maculopapular eruptions, supported our hypothesis. Our findings may improve the diagnosis of BNT162b2 vaccine-triggered elevated VZV-CF Ab titer-associated late-onset maculopapular eruptions and facilitate further investigation of diverse BNT162b2 vaccine-induced adverse events.</p>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/2777924","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/2777924","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Diverse cutaneous adverse reactions associated with the messenger RNA-based BNT162b2 coronavirus disease 2019 (COVID-19) vaccine have been reported, usually developing within 3 weeks after the first vaccination. However, the long-term cutaneous effects of this vaccine remain poorly understood. We hypothesized that the BNT162b2 vaccine might trigger late-onset (>4 weeks after the first dose) maculopapular eruptions associated with elevated varicella-zoster virus (VZV) complement-fixing antibody (VZV-CF Ab) titers indicative of recent subclinical VZV reactivation. Therefore, we conducted a hospital-based cross-sectional study at the Dermatology Department of Kita-Harima Medical Center, Ono City, Japan, between July 1, 2021, and June 30, 2022, to investigate the correlations among the BNT162b2 vaccine, maculopapular eruptions, and VZV-CF Ab titers. Fifteen eligible patients (EPs) who experienced maculopapular eruptions on the trunk and extremities no earlier than 4 weeks after the first BNT162b2 vaccine dose and 12 control patients (CPs) were enrolled. The mean age of EPs and CPs was 73.7 and 77.6 years, respectively, and the median interval between the first BNT162b2 vaccination and onset of maculopapular eruptions was 90 days. The median VZV-CF Ab titer of EPs was significantly higher than that of CPs (×8 vs. ×4). Although people of all ages, except children aged ≤12 years, received BNT162b2 vaccinations, all EPs were aged ≥57 years. All EPs presented between July 2021 and March 2022. There were no EPs from April 2022 to December 2023. These results suggest that the BNT162b2 vaccine triggers elevated VZV-CF Ab titer-associated maculopapular eruptions as late-onset cutaneous adverse reactions in older adults. Furthermore, the observation that two EPs concurrently experienced delayed large local reactions, also known as COVID arm, along with maculopapular eruptions, supported our hypothesis. Our findings may improve the diagnosis of BNT162b2 vaccine-triggered elevated VZV-CF Ab titer-associated late-onset maculopapular eruptions and facilitate further investigation of diverse BNT162b2 vaccine-induced adverse events.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
日本老年患者接种 BNT162b2 mRNA COVID-19 疫苗后,晚发性大疱性发作与水痘-带状疱疹病毒补体结合抗体滴度升高有关:一项横断面研究
据报道,与基于信使核糖核酸的 BNT162b2 冠状病毒病 2019(COVID-19)疫苗相关的皮肤不良反应多种多样,通常在首次接种后 3 周内出现。然而,人们对这种疫苗的长期皮肤效应仍然知之甚少。我们假设,BNT162b2 疫苗可能会引发晚发(第一剂接种后 4 周)斑丘疹,与水痘-带状疱疹病毒(VZV)补体固定抗体(VZV-CF Ab)滴度升高有关,这表明近期亚临床 VZV 再激活。因此,我们于 2021 年 7 月 1 日至 2022 年 6 月 30 日在日本大野市北播磨医疗中心皮肤科进行了一项医院横断面研究,以探讨 BNT162b2 疫苗、斑丘疹和 VZV-CF Ab 滴度之间的相关性。15 名符合条件的患者(EPs)和 12 名对照组患者(CPs)在接种第一剂 BNT162b2 疫苗后 4 周内躯干和四肢出现斑丘疹。EPs 和 CPs 的平均年龄分别为 73.7 岁和 77.6 岁,首次接种 BNT162b2 疫苗与出现斑丘疹之间的中位间隔为 90 天。EPs的VZV-CF抗体滴度中位数明显高于CPs(×8对×4)。虽然除≤12岁的儿童外,所有年龄段的人都接种了BNT162b2疫苗,但所有EP的年龄都≥57岁。所有 EP 均在 2021 年 7 月至 2022 年 3 月期间发病。2022 年 4 月至 2023 年 12 月期间没有 EP。这些结果表明,BNT162b2 疫苗会引发与 VZV-CF Ab 滴度升高相关的斑丘疹,这是老年人晚发的皮肤不良反应。此外,观察到两名 EP 同时出现迟发性大面积局部反应(也称为 COVID arm)和斑丘疹,也支持了我们的假设。我们的研究结果可能会改善对 BNT162b2 疫苗引发的 VZV-CF Ab 滴度升高相关晚发性斑丘疹的诊断,并有助于进一步调查 BNT162b2 疫苗诱发的各种不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Dermatologic Therapy
Dermatologic Therapy 医学-皮肤病学
CiteScore
7.00
自引率
8.30%
发文量
711
审稿时长
3 months
期刊介绍: Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.
期刊最新文献
Clinical Experience With Brentuximab Vedotin in Treating Cutaneous T-Cell Lymphoma: A Retrospective Review From China Pharmaceutical Management of Rosacea—An Australian/New Zealand Medical Dermatology Consensus Narrative A3669G Polymorphism of Glucocorticoid Receptor Is More Present in Patients With Pemphigus Vulgaris Than in Healthy Controls and Contributes to Steroid-Resistance Baricitinib for the Treatment of Chronic Pruritus of Unknown Origin Patient Awareness, Education, and Support for Atopic Dermatitis in Egypt and Lebanon: Results of a Physician Survey and Social Analytics
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1